DWTX
Dogwood Therapeutics, Inc.
Price Chart
Latest Quote
$1.55
+0.06 (+4.03%)
Current Price
| Previous Close | $1.49 |
| Open | $1.49 |
| Day High | $1.56 |
| Day Low | $1.42 |
| Volume | 74,860 |
Stock Information
| Shares Outstanding | 33.63M |
| Total Debt | $145K |
| Cash Equivalents | $13.23M |
| Net Income | $-28.32M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $52.13M |
| P/E Ratio | 1.32 |
| EPS (TTM) | $1.17 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $39.04M |
| Income | $-28.32M |
| Book/sh | $2.52 |
| Cash/sh | $0.39 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 5.17 |
| Current Ratio | 5.86 |
| Debt/Eq | 0.18 |
Returns & Margins
| ROA | -18.60% |
| ROE | -34.67% |
Ownership
| Insider Ownership | 74.49% |
| Institutional Ownership | 10.97% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.24 |
| P/B | 0.62 |
Analyst Data
| Recommendation | none |
| Target Price | $14.00 |
Technical Indicators
| SMA20 | $1.61 |
| SMA50 | $1.63 |
| SMA200 | $3.77 |
| RSI | 40.28 |
| ATR | 0.1223 |
| Shares Float | 5.11M |
| Short Float | 0.55% |
| Short Ratio | 0.80 |
| Volatility | 1.71 |
| Rel Volume | 0.90 |
Performance History
| Week | -1.27% |
| Month | -16.22% |
| Quarter | -42.91% |
| 6 Months | -75.89% |
| YTD | -63.44% |
| Year | -67.57% |
| 3 Years | -96.65% |
| 5 Years | -98.99% |
| 10 Years | -99.63% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.55 | 74,900 |
| 2026-06-17 | $1.49 | 511,900 |
| 2026-06-16 | $1.50 | 26,600 |
| 2026-06-15 | $1.57 | 70,700 |
| 2026-06-12 | $1.54 | 58,600 |
| 2026-06-11 | $1.57 | 266,400 |
| 2026-06-10 | $1.49 | 73,100 |
| 2026-06-09 | $1.45 | 40,500 |
| 2026-06-08 | $1.46 | 48,800 |
| 2026-06-05 | $1.50 | 49,900 |
| 2026-06-04 | $1.68 | 27,200 |
| 2026-06-03 | $1.61 | 85,600 |
| 2026-06-02 | $1.67 | 33,300 |
| 2026-06-01 | $1.70 | 37,000 |
| 2026-05-29 | $1.69 | 27,500 |
| 2026-05-28 | $1.67 | 26,800 |
| 2026-05-27 | $1.71 | 64,200 |
| 2026-05-26 | $1.78 | 84,100 |
| 2026-05-22 | $1.79 | 32,600 |
| 2026-05-21 | $1.81 | 33,800 |
| 2026-05-20 | $1.84 | 51,500 |
| 2026-05-19 | $1.85 | 53,200 |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
đ° Latest News
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval
Insider Monkey âĸ 2026-04-21T02:46:56Z
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron
MT Newswires âĸ 2025-12-22T16:00:01ZPotential Government Shutdown in Focus as US Equity Futures Rise Pre-Bell
MT Newswires âĸ 2025-09-29T13:08:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $27,968,445 | $12,227,248 | $5,446,919 | $12,315,309 |
| Other Income Expense | $-6,164,767 | $-30,787 | - | - |
| Net Non Operating Interest Income Expense | $96,938 | $-92,192 | $150,904 | $67,475 |
| Total Other Finance Cost | $-96,938 | $92,192 | - | $-67,475 |
| Operating Expense | $27,968,445 | $12,227,248 | $5,446,919 | $12,315,309 |
| General And Administrative Expense | $6,102,374 | $8,696,335 | $3,718,841 | $4,245,681 |
| Interest Expense | - | $92,192 | - | - |
| Interest Expense Non Operating | - | $92,192 | - | - |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-34,257,370 | $-12,349,724 | $-5,296,015 | $-12,247,834 |
| Net Interest Income | $96,938 | $-92,192 | $150,904 | $67,475 |
| Normalized Income | $-29,387,204 | $-12,318,938 | $-5,296,015 | $-12,247,834 |
| Net Income From Continuing And Discontinued Operation | $-34,257,370 | $-12,349,724 | $-5,296,015 | $-12,247,834 |
| Total Operating Income As Reported | $-27,968,445 | $-12,227,248 | $-5,446,919 | $-12,315,309 |
| Net Income Common Stockholders | $-35,514,032 | $-12,863,829 | $-5,296,015 | $-12,247,834 |
| Net Income | $-34,257,370 | $-12,349,724 | $-5,296,015 | $-12,247,834 |
| Net Income Including Noncontrolling Interests | $-34,257,370 | $-12,349,724 | $-5,296,015 | $-12,247,834 |
| Net Income Continuous Operations | $-34,257,370 | $-12,349,724 | $-5,296,015 | $-12,247,834 |
| Pretax Income | $-34,036,274 | $-12,350,227 | $-5,296,015 | $-12,247,834 |
| Special Income Charges | $-6,136,851 | $0 | - | - |
| Operating Income | $-27,968,445 | $-12,227,248 | $-5,446,919 | $-12,315,309 |
| Interest Income | - | - | $150,904 | $67,475 |
| Interest Income Non Operating | - | - | $150,904 | $67,475 |
| Per Share | ||||
| Diluted EPS | $-7.13 | $-12.52 | $-7.00 | $-27.75 |
| Basic EPS | $-7.13 | $-12.52 | $-7.00 | $-27.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,294,601 | $-1 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-21,801,615 | $-12,184,284 | $-5,446,919 | $-12,315,309 |
| Total Unusual Items | $-6,164,767 | $-30,787 | - | - |
| Total Unusual Items Excluding Goodwill | $-6,164,767 | $-30,787 | - | - |
| Reconciled Depreciation | $2,063 | $12,177 | $0 | - |
| EBITDA (Bullshit earnings) | $-27,966,382 | $-12,215,071 | $-5,446,919 | $-12,315,309 |
| EBIT | $-27,968,445 | $-12,227,248 | $-5,446,919 | $-12,315,309 |
| Diluted Average Shares | $4,977,446 | $1,027,788 | $751,071 | $442,804 |
| Basic Average Shares | $4,977,446 | $1,027,788 | $751,071 | $442,804 |
| Diluted NI Availto Com Stockholders | $-35,514,032 | $-12,863,829 | $-5,296,015 | $-12,247,834 |
| Preferred Stock Dividends | $1,256,662 | $514,105 | - | - |
| Tax Provision | $221,096 | $-503 | $0 | $0 |
| Gain On Sale Of Ppe | $-2,731 | $0 | - | - |
| Other Special Charges | $6,134,120 | - | - | - |
| Gain On Sale Of Security | $-27,916 | $-30,787 | - | - |
| Research And Development | $21,866,071 | $3,530,913 | $1,728,078 | $8,069,628 |
| Selling General And Administration | $6,102,374 | $8,696,335 | $3,718,841 | $4,245,681 |
| Other Gand A | $6,102,374 | $8,696,335 | $3,718,841 | $4,245,681 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,489,277 | $-13,241,980 | $3,806,894 | $7,326,494 |
| Total Assets | $90,171,237 | $94,308,246 | $4,165,442 | $8,369,756 |
| Total Non Current Assets | $81,740,031 | $77,763,784 | $0 | $0 |
| Non Current Deferred Assets | $158,956 | $0 | - | - |
| Goodwill And Other Intangible Assets | $81,386,144 | $77,523,003 | $0 | - |
| Other Intangible Assets | $68,985,026 | $65,710,527 | - | - |
| Current Assets | $8,431,206 | $16,544,462 | $4,165,442 | $8,369,756 |
| Other Current Assets | $4,876 | $28,006 | $3,559 | $7,291 |
| Prepaid Assets | $1,901,586 | $1,668,507 | $844,937 | $1,331,473 |
| Cash Cash Equivalents And Short Term Investments | $6,524,744 | $14,847,949 | $3,316,946 | $7,030,992 |
| Cash And Cash Equivalents | $6,524,744 | $14,847,949 | $3,316,946 | $7,030,992 |
| Cash Financial | $6,524,744 | $14,847,949 | $3,316,946 | $7,030,992 |
| Non Current Prepaid Assets | - | $18,133 | $0 | - |
| Debt | ||||
| Total Debt | $162,604 | $15,585,658 | $0 | - |
| Long Term Debt And Capital Lease Obligation | $105,763 | $15,535,962 | $0 | - |
| Current Debt And Capital Lease Obligation | $56,841 | $49,696 | - | - |
| Net Debt | - | $533,128 | - | - |
| Long Term Debt | - | $15,381,077 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,274,370 | $30,027,223 | $358,548 | $1,043,262 |
| Total Non Current Liabilities Net Minority Interest | $12,215,167 | $26,850,887 | $0 | $0 |
| Non Current Deferred Liabilities | $12,109,404 | $11,314,925 | $0 | - |
| Non Current Deferred Taxes Liabilities | $12,109,404 | $11,314,925 | $0 | - |
| Current Liabilities | $3,059,203 | $3,176,336 | $358,548 | $1,043,262 |
| Payables And Accrued Expenses | $2,257,282 | $2,389,359 | $358,548 | $883,558 |
| Interest Payable | $188,085 | $417,539 | $188,085 | $188,085 |
| Payables | $760,945 | $1,231,805 | $111,913 | $573,164 |
| Accounts Payable | $760,945 | $1,231,805 | $111,913 | $573,164 |
| Equity | ||||
| Common Stock Equity | $74,896,867 | $-10,124,339 | $3,806,894 | $7,326,494 |
| Total Equity Gross Minority Interest | $74,896,867 | $64,281,023 | $3,806,894 | $7,326,494 |
| Stockholders Equity | $74,896,867 | $64,281,023 | $3,806,894 | $7,326,494 |
| Gains Losses Not Affecting Retained Earnings | $-587,039 | $-3,862,987 | $0 | - |
| Other Equity Adjustments | $-587,039 | $-3,862,987 | - | - |
| Retained Earnings | $-108,076,316 | $-73,818,946 | $-61,469,222 | $-56,173,207 |
| Preferred Stock Equity | - | $74,405,362 | - | - |
| Other | ||||
| Treasury Shares Number | $7,718 | $7,718 | $7,718 | - |
| Ordinary Shares Number | $29,743,516 | $1,332,178 | $770,317 | $733,215 |
| Share Issued | $29,751,234 | $1,339,896 | $778,035 | $733,215 |
| Tangible Book Value | $-6,489,277 | $-87,647,342 | $3,806,894 | $7,326,494 |
| Invested Capital | $74,896,867 | $5,256,738 | $3,806,894 | $7,326,494 |
| Working Capital | $5,372,003 | $13,368,126 | $3,806,894 | $7,326,494 |
| Capital Lease Obligations | $162,604 | $204,581 | $0 | - |
| Total Capitalization | $74,896,867 | $79,662,100 | $3,806,894 | $7,326,494 |
| Treasury Stock | $299,128 | $299,128 | $299,128 | $0 |
| Additional Paid In Capital | $183,856,376 | $67,856,589 | $65,575,167 | $63,497,868 |
| Capital Stock | $2,974 | $74,405,495 | $77 | $1,833 |
| Common Stock | $2,974 | $133 | $77 | $1,833 |
| Preferred Stock | $0 | $74,405,362 | $0 | $0 |
| Long Term Capital Lease Obligation | $105,763 | $154,885 | $0 | - |
| Current Capital Lease Obligation | $56,841 | $49,696 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $745,080 | $737,281 | $0 | $159,704 |
| Current Accrued Expenses | $1,496,337 | $1,157,554 | $246,635 | $310,394 |
| Goodwill | $12,401,118 | $11,812,476 | $0 | - |
| Net PPE | $194,931 | $240,781 | $0 | - |
| Accumulated Depreciation | $0 | $-1,576 | - | - |
| Gross PPE | $194,931 | $242,357 | $0 | - |
| Construction In Progress | $19,037 | $18,133 | - | - |
| Other Properties | $163,140 | $205,837 | - | - |
| Machinery Furniture Equipment | $12,754 | $18,387 | - | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,618,651 | $-8,790,805 | $-4,870,489 | $-11,467,797 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,618,651 | $-8,790,805 | $-4,870,489 | $-11,467,797 |
| Cash Flow From Continuing Operating Activities | $-15,618,651 | $-8,790,805 | $-4,870,489 | $-11,467,797 |
| Operating Gains Losses | $30,647 | $30,787 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $3,761,936 | $0 | - |
| Cash Flow From Continuing Investing Activities | $0 | $3,761,936 | $0 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-351 | $0 | - |
| Issuance Of Capital Stock | $4,338,611 | $1,382,170 | $1,156,443 | $4,490,605 |
| Financing Cash Flow | $7,284,806 | $16,704,464 | $1,156,443 | $4,490,605 |
| Cash Flow From Continuing Financing Activities | $7,284,806 | $16,704,464 | $1,156,443 | $4,490,605 |
| Net Other Financing Charges | $-53,805 | - | - | - |
| Net Common Stock Issuance | $4,338,611 | $1,381,819 | $1,156,443 | $4,490,605 |
| Common Stock Issuance | $4,338,611 | $1,382,170 | $1,156,443 | $4,490,605 |
| Cash Dividends Paid | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $3,000,000 | $15,322,645 | $0 | - |
| End Cash Position | $6,524,744 | $14,847,949 | $3,316,946 | $7,030,992 |
| Beginning Cash Position | $14,847,949 | $3,316,946 | $7,030,992 | $14,008,184 |
| Effect Of Exchange Rate Changes | $10,640 | $-144,592 | $0 | - |
| Changes In Cash | $-8,333,845 | $11,675,595 | $-3,714,046 | $-6,977,192 |
| Common Stock Payments | $0 | $-351 | $0 | - |
| Net Issuance Payments Of Debt | $3,000,000 | $15,322,645 | $0 | - |
| Net Long Term Debt Issuance | $3,000,000 | $15,322,645 | $0 | - |
| Long Term Debt Issuance | $3,000,000 | $15,322,645 | $0 | - |
| Net Business Purchase And Sale | $0 | $3,761,936 | $0 | - |
| Sale Of Business | $0 | $3,761,936 | $0 | - |
| Change In Working Capital | $-133,004 | $-581,268 | $-194,446 | $197,378 |
| Change In Payables And Accrued Expense | $75,683 | $-82,551 | $-684,714 | $-232,361 |
| Change In Accrued Expense | $608,290 | $-302,439 | $-223,463 | $-451,662 |
| Change In Payable | $-532,607 | $219,888 | $-461,251 | $219,301 |
| Change In Account Payable | $-532,607 | $219,888 | $-461,251 | $219,301 |
| Change In Prepaid Assets | $-208,687 | $-498,717 | $490,268 | $429,739 |
| Other Non Cash Items | $18,162,275 | $3,621,705 | - | - |
| Stock Based Compensation | $355,642 | $476,021 | $619,972 | $582,659 |
| Deferred Tax | $221,096 | $-503 | $0 | - |
| Deferred Income Tax | $221,096 | $-503 | $0 | - |
| Depreciation Amortization Depletion | $2,063 | $12,177 | $0 | - |
| Depreciation And Amortization | $2,063 | $12,177 | $0 | - |
| Depreciation | $2,063 | $12,177 | $0 | - |
| Net Foreign Currency Exchange Gain Loss | $27,916 | $30,787 | $0 | - |
| Gain Loss On Sale Of PPE | $2,731 | $0 | - | - |
| Net Income From Continuing Operations | $-34,257,370 | $-12,349,724 | $-5,296,015 | $-12,247,834 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | - |
| Interest Paid Cff | - | - | - | - |
| Provisionand Write Offof Assets | - | - | - | - |
Fetched: 2026-06-21